Interested in Monitoring? Call 877-596-2224
Current Customers Call 877-296-6465
Patients & Other Questions Call 877-643-6179
Ameritox Chief Medical Officer & Senior Vice President Dr. Harry Leider, MD, MBA, FACPE, was interviewed by Pain Management magazine and PainLive.com, where he discussed pain management, pain medication monitoring and Ameritox’s Rx GuardianSM process, featuring Rx Guardian CDSM.
From Pain Management:
Anecdotal accounts and clinical studies alike indicate that primary care physicians and other clinicians who use opioid medications to treat patients for chronic pain are struggling to implement uniform and effective abuse and misuse assessment and risk management protocols. Urine drug testing is an important part of this process, but many non-pain specialists need additional guidance and resources to support their decision-making processes in terms of administering the tests and interpreting the results.
In this Q&A, Harry L. Leider, MD, MBA, FACPE, Chief Medical Officer and Senior Vice President of Ameritox, discusses the role of urine drug testing in pain management, and explains how Rx Guardian CD, a reference database and normalization algorithm, can help clinicians manage risk in their patients being treated with opioids.